Astrazeneca Pharmaceuticals AB, Sweden, holds 75 per cent stake in AstraZeneca Pharma India.
Astrazeneca Pharmaceuticals AB, the promoter of the company has informed that the "floor price in relation to the delisting proposal has been fixed at Rs 854.1 per equity share," the company said in a filing to the BSE.
AstraZeneca said that increase in promoter's ownership in the company will provide with greater operational flexibility to support the business.
Last month, AstraZeneca Pharma had received by email a letter from the promoter proposing to make a voluntary delisting offer to the public shareholders from stock exchanges.
Shares of the company today closed at Rs 1,092.80 a share on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
